Tampere University, Theravia Partner to Advance New EB Drug
Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB) to Theravia, a pharmaceutical company headquartered in Paris, France. Tampere University and Theravia will develop, register and commercialize the drug. Theravia will be responsible for further drug development and conducting clinical trials in EB patients. “Pre-clinical studies have shown that our drug molecule […]